Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
scientific article published on 22 October 2015
Author/s
author: Prudence Francis, José Luis Rodríguez-Peralto, Marco Colleoni, Olivia Pagani, Aron Goldhirsch, Meredith M Regan, Barbara A Walley, Gini F. Fleming, Karen L Price, Roswitha Kammler, Patrizia Dell'Orto, SOFT and TEXT Investigators and International Breast Cancer Study Group
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.